The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer

Overview

Journal J Urol

Publisher Wolters Kluwer

Specialty Urology

Date 2014 Dec 3

PMID 25463993

Citations 120

Authors

Stacy Loeb

Martin G Sanda

Dennis L Broyles

Sanghyuk S Shin

Chris H Bangma

John T Wei

Alan W Partin

George G Klee

Kevin M Slawin

Leonard S Marks

Ron H N van Schaik

Daniel W Chan

Lori J Sokoll

Amabelle B Cruz

Isaac A Mizrahi

William J Catalona

Affiliations

Soon will be listed here.

Abstract

Purpose: The Prostate Health Index (phi) is a new test combining total, free and [-2]proPSA into a single score. It was recently approved by the FDA and is now commercially available in the U.S., Europe and Australia. We investigate whether phi improves specificity for detecting clinically significant prostate cancer and can help reduce prostate cancer over diagnosis.

Materials And Methods: From a multicenter prospective trial we identified 658 men age 50 years or older with prostate specific antigen 4 to 10 ng/ml and normal digital rectal examination who underwent prostate biopsy. In this population we compared the performance of prostate specific antigen, % free prostate specific antigen, [-2]proPSA and phi to predict biopsy results and, specifically, the presence of clinically significant prostate cancer using multiple criteria.

Results: The Prostate Health Index was significantly higher in men with Gleason 7 or greater and "Epstein significant" cancer. On receiver operating characteristic analysis phi had the highest AUC for overall prostate cancer (AUCs phi 0.708, percent free prostate specific antigen 0.648, [-2]proPSA 0.550 and prostate specific antigen 0.516), Gleason 7 or greater (AUCs phi 0.707, percent free prostate specific antigen 0.661, [-2]proPSA 0.558, prostate specific antigen 0.551) and significant prostate cancer (AUCs phi 0.698, percent free prostate specific antigen 0.654, [-2]proPSA 0.550, prostate specific antigen 0.549). At the 90% sensitivity cut point for phi (a score less than 28.6) 30.1% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free prostate specific antigen.

Conclusions: The new phi test outperforms its individual components of total, free and [-2]proPSA for the identification of clinically significant prostate cancer. Phi may be useful as part of a multivariable approach to reduce prostate biopsies and over diagnosis.

Citing Articles

A preliminary follow-up study on irreversible electroporation therapy in older patients with prostate cancer.

Xia Z, Yang J, Xiao F, Xu J, Zhong X, Wang S Discov Oncol. 2025; 16(1):278.

PMID: 40053175 PMC: 11889298. DOI: 10.1007/s12672-025-02025-0.

Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer.

Kumar N Cancer Control. 2024; 31:10732748241302863.

PMID: 39573923 PMC: 11583501. DOI: 10.1177/10732748241302863.

Advancements in Biomarkers of Prostate Cancer: A Review.

Agbetuyi-Tayo P, Gbadebo M, Rotimi O, Rotimi S Technol Cancer Res Treat. 2024; 23:15330338241290029.

PMID: 39440372 PMC: 11497500. DOI: 10.1177/15330338241290029.

Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer.

Robinson H, Lee S, Barocas D, Tosoian J Prostate Cancer Prostatic Dis. 2024; 28(1):45-55.

PMID: 38858447 DOI: 10.1038/s41391-024-00840-0.

Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects.

Liu Y, Hatano K, Nonomura N World J Mens Health. 2024; 43(1):8-27.

PMID: 38772530 PMC: 11704174. DOI: 10.5534/wjmh.230386.

References

Khan M, Partin A, Rittenhouse H, Mikolajczyk S, Sokoll L, Chan D . Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol. 2003; 170(3):723-6. DOI: 10.1097/01.ju.0000086940.10392.93. View

Loeb S, Bjurlin M, Nicholson J, Tammela T, Penson D, Carter H . Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014; 65(6):1046-55. PMC: 4113338. DOI: 10.1016/j.eururo.2013.12.062. View

Ng C, Chiu P, Lam N, Lam H, Lee K, Hou S . The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol. 2013; 46(4):711-7. DOI: 10.1007/s11255-013-0582-0. View

DeLong E, Delong D, Clarke-Pearson D . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-45. View

Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M, COCKETT A . Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993; 150(1):100-5. DOI: 10.1016/s0022-5347(17)35408-3. View

Qin G, Hsu Y, Zhou X . New confidence intervals for the difference between two sensitivities at a fixed level of specificity. Stat Med. 2005; 25(20):3487-502. DOI: 10.1002/sim.2459. View

Carter H, Kettermann A, Warlick C, Metter E, Landis P, Walsh P . Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007; 178(6):2359-64. PMC: 4390051. DOI: 10.1016/j.juro.2007.08.039. View

Tosoian J, Loeb S, Kettermann A, Landis P, Elliot D, Epstein J . Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol. 2009; 183(2):534-8. DOI: 10.1016/j.juro.2009.10.003. View

Jansen F, van Schaik R, Kurstjens J, Horninger W, Klocker H, Bektic J . Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol. 2010; 57(6):921-7. DOI: 10.1016/j.eururo.2010.02.003. View

10.

Isharwal S, Makarov D, Sokoll L, Landis P, Marlow C, Epstein J . ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology. 2011; 77(3):763.e1-6. PMC: 4696012. DOI: 10.1016/j.urology.2010.07.526. View

11.

Catalona W, Partin A, Sanda M, Wei J, Klee G, Bangma C . A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011; 185(5):1650-5. PMC: 3140702. DOI: 10.1016/j.juro.2010.12.032. View

12.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104(2):125-32. PMC: 3260132. DOI: 10.1093/jnci/djr500. View

13.

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981-90. PMC: 6027585. DOI: 10.1056/NEJMoa1113135. View

14.

Moyer V . Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(2):120-34. DOI: 10.7326/0003-4819-157-2-201207170-00459. View

15.

Tosoian J, Loeb S, Feng Z, Isharwal S, Landis P, Elliot D . Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol. 2012; 188(4):1131-6. PMC: 3976250. DOI: 10.1016/j.juro.2012.06.009. View

16.

Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A . Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem. 2012; 59(1):306-14. DOI: 10.1373/clinchem.2012.195784. View

17.

Filella X, Gimenez N . Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med. 2012; 51(4):729-39. DOI: 10.1515/cclm-2012-0410. View

18.

Ito K, Miyakubo M, Sekine Y, Koike H, Matsui H, Shibata Y . Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol. 2012; 31(2):305-11. DOI: 10.1007/s00345-012-0927-9. View

19.

Lazzeri M, Haese A, De La Taille A, Palou Redorta J, McNicholas T, Lughezzani G . Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol. 2013; 63(6):986-94. DOI: 10.1016/j.eururo.2013.01.011. View

20.

Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Perruolo G . Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One. 2013; 8(7):e67687. PMC: 3701535. DOI: 10.1371/journal.pone.0067687. View